Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25
Press Release: Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to Its Board of Directors
Express News | Candel Therapeutics Appoints Maha Radhakrishnan, M.d., to Its Board of Directors
Buy Recommendation for Candel Therapeutics: Promising Data on CAN-2409 Treatment for Prostate Cancer
Sector Update: Health Care Stocks Softer Late Afternoon
Small Cap Wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE...
Market Movers: GameStop, Okta, Abercrombie, Candel Therapeutics...
Candel Shares Rise After FDA Regenerative Medicine Advanced Therapy Designation
Shares of Candel Therapeutics Are Trading Higherafter the Company Announced It Received Regenerative Medicine Advanced Therapy Designation From the FDA for Its Lead Candidate, CAN-2409.
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
Candel Therapeutics Receives FDA RMAT Designation to CAN-2409
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
Express News | Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Can-2409 for the Treatment of Prostate Cancer
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
Small Cap Wrap: Excellon Resources, Candel Therapeutics, Forte Minerals...
Candel Therapeutics Unveils Promising Phase 3 Trial Results
Express News | Candel Therapeutics Inc - Can-2409 Well Tolerated With Low Incidence of Serious Adverse Events
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Express News | Candel Therapeutics Presents Positive Phase 3 Can-2409 Results in Localized Prostate Cancer at Asco 2025
BofA Securities Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $15